Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines

Clinical and Experimental Immunology

Volumn 148, Issue 1, 2007, Pages 127-135

  Pandha, H ^a   Rigg, A ^b   John, J ^c   Lemoine, N ^d  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antigen presenting; Cancer; Human; Pancreatic

Indexed keywords

CARRIER PROTEIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; TRANSPORTER ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; IN VITRO STUDY; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; DOWN-REGULATION; FEMALE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PHENOTYPE; TUMOR CELLS, CULTURED;

EID: 33847684243     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03289.x     Document Type: Article

References (41)

1. Hruban RH. Pancreatic cancer: from genes to patient care. J Gastro Intest Surg 2001; 5:583-7.
2. Johnsen AK, Templeton DJ, SyM,Harding CV. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1999; 163:4224-31.
3. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177:265-72.
4. Alpan RS, Zhang M, Pardee AB. Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res 1996; 56:4358-61.
5. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996; 13:210-3.
6. Cromme FV, Airey J, Heemels MT et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179:335-40.
7. Cromme FV, van Bommel PF,Walboomers JM et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 1994; 69:1176-81.
8. Johnsen A, France J, Sy MS, Harding CV. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class Imajor histocompatibility complex in tumor cell lines. Cancer Res 1998; 58:3660-7.
9. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 1995; 55:5191-4.
10. Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, Mortensen N, Harris AL, Gatter KC. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol 1994; 145:505-9.
11. Keating PJ, Cromme FV, Duggan-Keen M et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995; 72:405-11.
12. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer, 1996; 73:148-53.
13. Kurokohchi K, Carrington M, Mann DL et al. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 1996; 23:1181-8.
14. Maeurer MJ, Gollin SM, Martin D et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996; 98:1633-41.
15. Rowe M, Khanna R, Jacob CA et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995; 25:1374-84.
16. Sanda MG, Restifo NP, Walsh JC et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995; 87:280-5.
17. Seliger B, Hohne A, Knuth A et al. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 1996; 2:1427-33.
18. Seliger B, Hohne A, Knuth A et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 1996b; 56:1756-60.
19. Singal DP, YeM,Ni J, Snider DP.Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines. Immunol Lett 1996; 50:149-54.
20. Vitale M, Rezzani R, Rodella L et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) downregulation in high-grade primary breast carcinoma lesions. Cancer Res 1998; 58:737-42.
21. Dotto GP, Parada LF, Weinberg RA. Specific growth response of ras-transformed embryo fibroblasts to tumour promoters. Nature 1985; 318:472-5.
22. Kaklamanis L, Gatter KC, Hill AB et al. Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int J Cancer 1992; 51:379-85.
23. Torres MJ, Ruiz-Cabello F, Skoudy A et al. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumour derived cell line. Tissue Antigens 1996; 47:372-81.
24. Lee JE,Abdalla J, Porter GA et al. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol 2002; 9:587-93.
25. Adams TE, Bodmer JG, Bodmer WF. Production and characterization of monoclonal antibodies recognizing the alpha-chain subunits of human ia alloantigens. Immunology 1983; 50:613-24.
26. Watson AJ, DeMars R, Trowbridge IS, Bach FH. Detection of a novel human class II HLA antigen. Nature 1983; 304:358-61.
27. Loiseau P, Lehn P, Dautry F et al. Correlation between an HLA-DQ alpha length polymorphism of messenger RNA and serologically defined specificities (DQw1, DRw53, DR3+5). Immunogenetics 1986; 23:111-14.
28. Welsh K, Bunce M. Molecular typing for the MHC with PCR-SSP. Rev Immunogen 1999; 1:157-76.
29. Scupoli MT, Sartoris S, Tosi G et al. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens 1996; 48:301-11.
30. Natali PG, Nicotra MR, Bigotti A et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 1989; 86:6719-23.
31. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16:487-94.
32. Momburg F, Degener T, Bacchus E, Moldenhauer G, Hammerling GJ,Moller P. Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 1986; 37:179-84.
33. Lopez-Nevot MA, Garcia E, Romero C, Oliva MR, Serrano S, Garrido F. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet 1988; 5:203-12.
34. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991; 2:47-54.
35. Esteban F,Concha A,Huelin C et al. Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 1989; 43:436-42.
36. Gudmundsdottir I, Gunnlaugur Jonasson J, Sigurdsson H, Olafsdottir K, Tryggvadottir L, Ogmundsdottir HM. Altered expression of HLA class I antigens in breast cancer association with prognosis. Int J Cancer 2000; 89:500-5.
37. Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M. Expression of HLA-A, B, C antigens on primary and metastatic tumour cell populations of human carcinomas. Cancer Res 1991; 51:6372-80.
38. Kamarashev J, Ferrone S, Seifert B et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer 2001; 95:23-8.
39. Zimmer J, Andres E, Donato L, Hanau D, Hentges F, de la Salle H. Clinical and immunological aspects of HLA class I deficiency. Q J Med 2005; 98:719-27.
40. Samukawa T. Expression of HLA-DR antigen on head and neck carcinomas - immunohistological study. 1993;96:88-97.
41. van Vreeswijk H, Ruiter DJ, Brocker EB, Welvaart K, Ferrone S. Differential expreesion ofHLA-DR,DQandDPantigens in primary and metastatic melanoma. J Invest Dermatol 1988; 90:755-60.